Introduction: The early identification of precursor lesions followed by appropriate treatment prevents development of cervical cancer and its consequences. Objective: The present study evaluated the influence of the COVID-19 pandemic on cervical cancer screening by comparing the quantity of tests to detect cervical cellular changes performed in São Paulo state in 2019, prior to the detection of SARS-CoV-2 in Brazil, to the first (2020) and second (2021) years following its appearance. Materials and Methods: Data from Fundação Oncocentro de São Paulo (FOSP), the agency that analyses approximately 220,000 Papanicolaou (Pap) tests annually, were reviewed. Results: A median of 1,835 Pap tests were performed in 55 municipalities in 2019. This was reduced to 815 tests in 2020, a 56% decrease (p = 0.0026). In 2021, the median number was 1,745, a 53% increase over 2020 levels (p = 0.0233). The 26 municipalities with #x3e;1,000 tests in 2020 had a median reduction from 4,433 in 2019 to 2,580 in 2020 (p = 0. 0046). The 29 municipalities with #x3c;1,000 tests had a median reduction from 951 in 2019 to 554 in 2020 (p #x3c; 0.0001). There was a 44% reduction in the number of follow-up cytological evaluations from 2019 to 2020, followed by a 30% increase in the following year. However, the percentage of women with a normal finding or with any abnormality remained unchanged. The findings from a histological evaluation of women in São Paulo city indicated that the percent of cases positive for CIN-1 (p #x3c; 0.0410) and CIN-3 (p #x3c; 0.0012) increased in 2020 and 2021 as compared to 2019 levels. Conclusion: A reduction in testing for cervical cancer in the first year of the COVID-19 pandemic, accompanied by an elevated incidence of precancerous lesions in each of the first 2 years following its initiation, may portend a subsequent increased occurrence of cervical cancer in Brazil.
Acta Cytologica

中文翻译：

---

COVID-19 大流行对巴西圣保罗州宫颈癌筛查的影响

简介：及早发现前兆病变，然后进行适当的治疗可预防宫颈癌的发展及其后果。目的：本研究通过比较 2019 年在巴西检测 SARS-CoV-2 之前在圣保罗州进行的检测宫颈细胞变化的检测数量，评估了 COVID-19 大流行对宫颈癌筛查的影响。到它出现后的第一年（2020 年）和第二年（2021 年）。材料和方法：审查了来自圣保罗肿瘤中心 (FOSP) 的数据，该机构每年分析大约 220,000 次巴氏试验。结果：2019 年在 55 个城市进行的巴氏试验的中位数为 1,835 次。到 2020 年，这一数字减少到 815 次，减少了 56% ( p = 0.0026)。2021 年，中位数为 1,745，比 2020 年水平增长 53% ( p = 0.0233)。26 个城市在 2020 年进行了#x3e;1,000 次测试，中位数从 2019 年的 4,433 次减少到 2020 年的 2,580 次（p = 0. 0046）。拥有#x3c;1,000 个测试的 29 个城市的测试中位数从 2019 年的 951 个减少到 2020 年的 554 个（p#x3c; 0.0001）。从 2019 年到 2020 年，后续细胞学评估的数量减少了 44%，随后一年增加了 30%。然而，具有正常发现或任何异常的女性百分比保持不变。对圣保罗市妇女进行的组织学评估结果表明，与 2019 年相比，2020 年和 2021 年CIN-1 ( p #x3c; 0.0410) 和 CIN-3 ( p #x3c; 0.0012)阳性病例百分比有所增加水平。结论：在 COVID-19 大流行的第一年，宫颈癌检测减少，伴随着开始后头 2 年每年癌前病变的发病率升高，可能预示着巴西宫颈癌的发病率随后会增加。
细胞学报